# A mandatory patient-experience section in every cancer drug label and approval

Source: https://onco.cc/ideas/idea-moon-patient-experience-label/  
OnCo record `idea-moon-patient-experience-label` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The official information about a new cancer drug must include what patients on the trial actually reported about side-effects and daily life, not only survival curves.

## Summary

The FDA Oncology Center of Excellence's Project Patient Voice began publishing patient-reported symptom data from trials, but labels remain silent on patient-reported outcomes for most drugs. The proposal is a required, standardised patient-experience section (PRO-CTCAE symptom frequency, physical function trajectory, time toxicity) in every oncology label and public assessment report, and a voting patient member on advisory committees with access to the same data.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Labels with patient-experience sections change prescribing towards better-tolerated regimens when efficacy is similar and increase sponsors' collection of high-quality PRO data in registrational trials.
- Rationale: Sponsors collect what regulators read. Making patient experience a labelled claim gives it commercial value and standardises how it is measured.
- Proposed test: Regulator pilots the section for all approvals over two years; survey prescribers and measure uptake of PRO instruments in subsequent pivotal protocols.
- Maturity: early-clinical
- Actor: regulator

## Sources

- FDA Project Patient Voice: https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice

## Connected records

- bottlenecks: [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-patient-experience-label.json